Pi-Cardia completes first-in-human mitral valve splitting with ShortCut

[Image from Pi-Cardia’s website]Pi-Cardia announced today that it completed a successful first-in-human treatment of the mitral valve with its ShortCut device.

Rehovot, Israel-based Pi-Cardia designed ShortCut to split the leaflets prior to transcatheter valve treatment in patients at risk for coronary obstruction after transcatheter aortic valve replacement (TAVR) or left ventricular outflow tract (LVOT) obstruction after transcatheter mitral valve replacement (TMVR).

The company said in a news release that ShortCut represents the world’s first dedicated device designed to split the leaflets prior to valve treatment.

Prof. Lenard Conradi and Dr. Niklas Schofer, in collaboration with Dr. Paolo Denti, performed the ShortCut Mitral compassionate case at the University Hamburg Eppendorf, Germany.

“We were able to successfully treat a patient who was at risk of LVOT obstruction by effectively splitting the anterior leaflet in a simple a…

Read more
  • 0